Investors who own more than 5% of a class must file a Schedule 13D or 13G. Each filer's latest filing for 88032L605 since 12/18/2024, largest first.
| Filer | % of Class | Filed | ||
|---|---|---|---|---|
|
ADAR1 Capital Management, LLC
13G
|
14.0% |
9/8/2026
Event 8/31/2026
|
||
| ADAR1 Capital Management, LLC | 14.0% | |||
| Daniel Schneeberger | 14.0% | |||
|
Biotechnology Value Fund L P
13G/A
|
10.0% |
8/14/2026
Event 6/30/2026
|
||
| Biotechnology Value Fund L P | 9.5% | |||
| BVF I GP LLC | 9.5% | |||
| Biotechnology Value Fund II LP | 0.5% | |||
| BVF II GP LLC | 0.5% | |||
| Biotechnology Value Trading Fund OS LP | 0% | |||
| BVF Partners OS Ltd. | 0% | |||
| BVF GP Holdings LLC | 10.0% | |||
| BVF Partners L P/IL | 10.0% | |||
| BVF Inc/IL | 10.0% | |||
| Lampert Mark N | 10.0% | |||
| Janus Henderson Group PLC 13G | 10.0% |
12/8/2025
Event 11/28/2025
|
||
|
RTW Investments, LP
13G/A
|
9.9% |
8/14/2026
Event 6/30/2026
|
||
| RTW Investments, LP | 9.9% | |||
| Roderick Wong | 9.9% | |||
|
Vestal Point Capital, LP
13G
|
9.9% |
11/14/2025
Event 9/30/2024
|
||
| Vestal Point Capital, LP | 9.9% | |||
| Ryan Wilder | 9.9% | |||
|
Vivo Opportunity Fund Holdings, L.P.
13G/A
|
9.0% |
8/14/2026
Event 6/30/2026
|
||
| Vivo Opportunity Fund Holdings, L.P. | 9.0% | |||
| Vivo Opportunity, LLC | 9.0% | |||
|
Adage Capital Management, L.P.
13G/A
|
6.8% |
8/12/2026
Event 6/30/2026
|
||
| Adage Capital Management, L.P. | 6.8% | |||
| Robert Atchinson | 6.8% | |||
| Phillip Gross | 6.8% | |||
|
Dellora Investments LP
13G/A
|
6.4% |
10/9/2026
Event 10/2/2026
|
||
| Dellora Investments Master Fund LP | 5.5% | |||
| Dellora Investments LP | 6.4% | |||
| Kevin Pyun | 6.4% | |||
| BlackRock, Inc. 13G | 6.4% |
7/30/2026
Event 6/30/2026
|
||
|
Millennium Management LLC
13G
|
5.8% |
8/18/2026
Event 8/13/2026
|
||
| Millennium Management LLC | 5.8% | |||
| Millennium Group Management LLC | 5.8% | |||
| Israel A. Englander | 5.8% | |||
|
Sphera Funds Management Ltd.
13G
|
5.3% |
8/27/2026
Event 8/17/2026
|
||
| Sphera Funds Management Ltd. | 5.3% | |||
| Sphera Global Healthcare GP Ltd. | 5.3% | |||
| Sphera Global Healthcare Management LP | 5.3% | |||
| Under 5%, checked the "5 percent or less" box, or amended by a later filing (15) | ||||
| S.H.N. Financial Investments Ltd. 13G/A | 4.99% |
3/18/2025
Event 12/31/2024
|
||
|
Venrock Healthcare Capital Partners III, L.P.
13G/A
|
4.7% |
8/14/2026
Event 6/30/2026
|
||
| Venrock Healthcare Capital Partners III, L.P. | 4.7% | |||
| VHCP Co-Investment Holdings III, LLC | 4.7% | |||
| Venrock Healthcare Capital Partners EG, L.P. | 4.7% | |||
| VHCP Management III, LLC | 4.7% | |||
| VHCP Management EG, LLC | 4.7% | |||
| Nimish Shah | 4.7% | |||
| Bong Y. Koh | 4.7% | |||
|
Perceptive Advisors LLC
13G/A
|
4.5% |
8/14/2026
Event 6/30/2026
|
||
| Perceptive Advisors LLC | 4.5% | |||
| Joseph Edelman | 4.5% | |||
| Perceptive Life Sciences Master Fund, Ltd. | 4.5% | |||
| Christopher Thomas Giordano 13D/A | 4.3% |
7/31/2026
Event 7/31/2026
|
||
|
Stonepine Capital Management, LLC
13G/A
|
3.7% |
5/15/2026
Event 3/31/2026
|
||
| Stonepine Capital Management, LLC | 3.7% | |||
| Stonepine Capital, L.P. | 3.7% | |||
| Stonepine GP, LLC | 3.7% | |||
| Jon M. Plexico | 3.7% | |||
|
Morgan Stanley
13G/A
|
3.5% |
4/8/2026
Event 3/31/2026
|
||
| Morgan Stanley | 3.5% | |||
| Morgan Stanley Capital Services LLC | 3.4% | |||
|
Point72 Asset Management, L.P.
13G/A
|
3.1% |
5/15/2026
Event 3/31/2026
|
||
| Point72 Asset Management, L.P. | 3.1% | |||
| Point72 Capital Advisors, Inc. | 3.1% | |||
| Steven A. Cohen | 3.1% | |||
|
Logos Global Management LP
13G/A
|
3.0% |
5/15/2026
Event 3/31/2026
|
||
| Logos Global Management LP | 3.0% | |||
| Logos Global Management GP LLC | 3.0% | |||
| Logos Global Master Fund LP | 3.0% | |||
| Logos GP LLC | 3.0% | |||
| Arsani William | 3.0% | |||
|
Ikarian Capital, LLC
13G/A
|
2.9% |
8/14/2026
Event 6/30/2026
|
||
| Ikarian Capital, LLC | 2.9% | |||
| Neil Shahrestani | 2.9% | |||
|
Invus Global Management, LLC
13G/A
|
2.5% |
5/4/2026
Event 3/31/2026
|
||
| Invus Public Equities, L.P. | 2.1% | |||
| Invus Public Equities Advisors, LLC | 2.1% | |||
| Invus Global Management, LLC | 2.1% | |||
| Siren, L.L.C. | 2.1% | |||
| Avicenna Life Sci Master Fund LP | 0.4% | |||
| Avicenna Life Sci Master GP LLC | 0.4% | |||
| Ulys, L.L.C. | 0.4% | |||
| Raymond Debbane | 2.5% | |||
| Price T Rowe Associates Inc /MD/ 13G/A | 2.2% |
6/5/2026
Event 5/31/2026
|
||
|
Integrated Core Strategies (US) LLC
13G/A
|
2.1% |
5/8/2026
Event 3/31/2026
|
||
| Integrated Core Strategies (US) LLC | 1.7% | |||
| Millennium Management LLC | 2.1% | |||
| Millennium Group Management LLC | 2.1% | |||
| Israel A. Englander | 2.1% | |||
|
FMR LLC
13G/A
|
1.4% |
9/8/2026
Event 8/31/2026
|
||
| FMR LLC | 1.4% | |||
| Abigail P. Johnson | 1.4% | |||
|
Lind Global Fund II LP
13G/A
|
0.8% |
5/15/2026
Event 3/31/2026
|
||
| Lind Global Fund II LP | 0.8% | |||
| Lind Global Partners II LLC | 0.8% | |||
| Easton Jeff | 0.8% | |||
|
ING Groep N.V.
13G/A
|
0% |
9/11/2026
Event 9/3/2026
|
||
| ING Groep N.V. | 0% | |||
| ING Capital Markets LLC | 0% | |||
| Period | Filings | Shares, Excl. Options | Value, Excl. Options |
|---|---|---|---|
| 2026 Q3 | 1 | 2.59 k | $4.90 k |
| 2026 Q2 | 129 | 30.3 M | $442 M |
| 2026 Q1 | 85 | 21.8 M | $348 M |
| 2025 Q4 | 50 | 7.06 M | $86.1 M |
| 2025 Q3 | 34 | 4.72 M | $35.9 M |
| 2025 Q2 | 27 | 2.23 M | $12.9 M |
| 2025 Q1 | 24 | 2.01 M | $13.1 M |
| 2024 Q4 | 22 | 1.36 M | $8.43 M |
| 2024 Q3 | 20 | 1.23 M | $4.25 M |
| 2024 Q2 | 13 | 19.1 k | $58.0 k |
| 2024 Q1 | 12 | 7.76 k | $32.7 k |